期刊文献+

阿齐沙坦对转化生长因子诱导的自发性高血压大鼠血管平滑肌细胞增殖及迁移的影响 被引量:3

Effects of Azilsartan on TGF-β Induced Spontaneously Hypertensive Vascular Smooth Muscle Cells Proliferation and Migration
下载PDF
导出
摘要 目的探讨阿齐沙坦对转化生长因子-β(TGF-β)诱导的自发性高血压大鼠血管平滑肌细胞(VSMCs)增殖及迁移的影响。方法采用组织块贴壁培养法进行血管平滑肌细胞的原代培养,取3~5代细胞用于实验。用MTT法测定细胞增殖情况,用Boyden小室测试细胞迁移情况。采用10ng/ml TGF-β刺激VSMCs,并用阿齐沙坦干预,24h后用Western blot和RT-PCR检测VSMCs中MMP-2、MMP-9及TIMP-1蛋白和mRNA的表达。结果 TGF-β可促进大鼠VSMCs的增殖及迁移,并增加大鼠VSMCs的MMP-2、MMP-9和TIMP-1蛋白表达。阿齐沙坦则可抑制TGF-β诱导的大鼠VSMCs的增殖和迁移,并降低大鼠VSMCs的MMP-2、MMP-9及TIMP-1表达。结论阿齐沙坦可能通过下调MMP-2、MMP-9及TIMP-1的表达来抑制TGF-β诱导的自发性高血压血管平滑肌细胞的增殖及迁移。 Objective To investigate the effects of azilsartan on TGF-β-induced spontaneously hypertensive vascular smooth muscle cells( VSMCs) proliferation and migration. Methods Rat VSMCs were cultivated by the method of tissue explants adherence. Cells of generation 3 to 5 were used as the experimental system. The MTT test was used to measure cell proliferation and Boyden chamber assay was used to measure cell migration. Primary cultured VSMCs were treated by 10 ng /ml TGF-β and azilsartan for 24 hours. The expression of MMP-2,MMP-9,TIMP-1 were measured by Western blot and RT-PCR. Results The expression of MMP-2,MMP-9 and TIMP-1 in rat VSMCs stimulated by TGF-β increased significantly. VSMCs migration and proliferation also increased significantly. Azilsartan significantly inhibited TGF-β induced MMP-2,MMP-9 and TIMP-1production in rat VSMCs,as well as VSMCs proliferation and migration. Conclusions Azilsartan inhibited TGF-β-induced VSMCs proliferation and migration by down-regulation the expression of MMP-2,MMP-9,TIMP-1.
出处 《心脑血管病防治》 2014年第4期274-276,283,共4页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
关键词 MMP-2 MMP-9 TIMP-1 血管平滑肌细胞 增殖 迁移 阿齐沙坦 MMP-2 MMP-9 TIMP-1 Vascular smooth muscle cells Proliferation Migration Azilsartan
  • 相关文献

参考文献9

  • 1李超民,拓步雄.基质金属蛋白酶及其抑制物与原发性高血压[J].中华高血压杂志,2008,16(9):779-781. 被引量:5
  • 2Orbe J,Fernandez L,Rodriguez J A,et al.Different expression of MMPs/TIMP-1 in human atherosclerotic lesions.Relation to plaque features and vascular bed[J].Atherosclerosis,2003,170(2):269-276.
  • 3Sada T,Mizuno M.Pharmacological profiles and clinical effects of olmesartan medoxomil,a novel angiotensin II receptor blocker[J].Nihon Yakurigaku Zasshi,2004,124(4):257-269.
  • 4Lastra G,Santos FR,Hooshmand P,et al.The Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil Ameliorates Insulin Resistance Induced by Chronic Angiotensin II Treatment in Rat Skeletal Muscle[J].Cardiorenal Med,2013,3(2):154-164.
  • 5Amaral SL,Michelini LC.Effect of gender on training-induced vascular remodeling in SHR[J].Braz J Med Biol Res,2011,44(9):814-826.
  • 6邢爱敏.抗高血压药物阿齐沙坦酯[J].药学进展,2011,35(5):235-236. 被引量:4
  • 7Ergul A,Portik-Dobos V,Giulumian AD,et al.Stress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation[J].Am J Physiol Heart Circ Physiol,2003,285(5):H2225-H2232.
  • 8Watts SW,Rondelli C,Thakali K,et al.Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats[J].Am J Physiol Heart Circ Physiol,2007,292(5):H2438-H2448.
  • 9Fontana V,Silva PS,Izidoro-Toledo TC,et al.Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension[J].Cardiovascular drugs and therapy,2012,26(6):511-519.

二级参考文献19

  • 1[1]Tayebjee MH,MacFadyen RJ,Lip GY.Extracellular matrix biology:a new frontier in linking the pathology and therapy of hypertension[J].J Hypertens,2003,21:2211-2218.
  • 2[2]Ahmed SH,Clark LL,Pennington WR,et al.Matrix metalloproteinases/tissue inhibitors of metalloproteinases:relationship between changes in proteolytic determinants of matrix composition and structural,functional,and clinical manifestations of hypertensive heart disease[J].Circulation.2006,113:2089-2096.
  • 3[3]Matsusaka H,Ide T,Matsushima S,et al.Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload[J].Hypertension,2006,47:711-717.
  • 4[4]Tayebjee MH,Nadar SK,MacFadyen RJ,et al.Tissue inhibitor of metaUoproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension:Relationship to tissue Doppler indices of diastolic relaxation[J].Am J Hypertens,2004,17:770-774.
  • 5[5]Lindsay MM,Maxwell P,Dunn FG.TIMP-1:a marker of left vcntricular diastolic dysfunction and fibrosis in hypertension[J].Hypertension,2002,40:136-141.
  • 6[6]Camp TM,Smiley LM,Hayden MR,et al.Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats[J].J Hypertens,2003,21:1719-1727.
  • 7[7]Bolbrinker J,Markovic S,Wehland M,et al.Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension[J].J Pharmacol Exp Ther,2006,316:8-16.
  • 8[8]Ergul A,Portik-Dobos V,Hutchinson J,et al.Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients[J].Am J Hypertens,2004,17:775-782.
  • 9[9]Lehoux S,LemariéCA,Esposito B,et al.Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling[J].Circulation,2004,109:1041-1047.
  • 10[10]Spiers JP,Kelso EJ,Siah WF,et al.Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension:effects of endothelin receptor blockade[J].J Hypertens,2005,23:1717-1724.

共引文献7

同被引文献32

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部